- Home
- ZVRA vs IMAB Comparison
ZVRA vs IMAB Comparison
Compare ZVRA & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZVRA
- IMAB
- Stock Information
- Founded
- ZVRA 2006
- IMAB 2014
- Country
- ZVRA United States
- IMAB United States
- Employees
- ZVRA N/A
- IMAB N/A
- Industry
- ZVRA Biotechnology: Pharmaceutical Preparations
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- ZVRA Health Care
- IMAB Health Care
- Exchange
- ZVRA Nasdaq
- IMAB Nasdaq
- Market Cap
- ZVRA 467.6M
- IMAB 384.6M
- IPO Year
- ZVRA 2015
- IMAB 2020
- Fundamental
- Price
- ZVRA $7.33
- IMAB $3.69
- Analyst Decision
- ZVRA Strong Buy
- IMAB Strong Buy
- Analyst Count
- ZVRA 10
- IMAB 5
- Target Price
- ZVRA $22.67
- IMAB $6.80
- AVG Volume (30 Days)
- ZVRA 1.3M
- IMAB 1.7M
- Earning Date
- ZVRA 11-11-2025
- IMAB 11-02-2025
- Dividend Yield
- ZVRA N/A
- IMAB N/A
- EPS Growth
- ZVRA N/A
- IMAB N/A
- EPS
- ZVRA N/A
- IMAB N/A
- Revenue
- ZVRA $62,020,000.00
- IMAB N/A
- Revenue This Year
- ZVRA $329.57
- IMAB N/A
- Revenue Next Year
- ZVRA $55.29
- IMAB N/A
- P/E Ratio
- ZVRA N/A
- IMAB N/A
- Revenue Growth
- ZVRA 161.81
- IMAB N/A
- 52 Week Low
- ZVRA $6.19
- IMAB $0.60
- 52 Week High
- ZVRA $13.16
- IMAB $5.90
- Technical
- Relative Strength Index (RSI)
- ZVRA 22.63
- IMAB 45.33
- Support Level
- ZVRA $8.65
- IMAB $3.20
- Resistance Level
- ZVRA $9.48
- IMAB $4.64
- Average True Range (ATR)
- ZVRA 0.39
- IMAB 0.41
- MACD
- ZVRA -0.11
- IMAB -0.17
- Stochastic Oscillator
- ZVRA 7.36
- IMAB 29.88
About ZVRA Zevra Therapeutics Inc.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).